AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01060748 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03130907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of ureteral stent
Description: will randomize groups to either receive a postoperative ureteral stent or not.
Study NCT03130907 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of ureteral stent
Description: will randomize groups to either receive a postoperative ureteral stent or not.
Study NCT02295228 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There are no interventions. This is an observational trial.
Study NCT05879393 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OMNi-BiOTiC® Active
Description: Multistrain probiotic
Study NCT05879393 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: rice starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate
Study NCT03936907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OWCP Orally Disintegrating Tablet
Description: Medical Grade Cannabis - Orally Disintegrating Tablet (MGC-ODT) containing 5 mg THC and 5 mg CBD
Study NCT03936907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sativex
Description: Sativex® Oromucosal Spray
Study NCT04405999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromhexine Hydrochloride
Description: Medical personnel at risk for COVID-19 infection will receive study medication for 14 days
Study NCT04231682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab Injection
Description: Use of denosumab in post liver transplant patient for prevention and management of osteoporosis and bone loss.
Study NCT04231682 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Use of placebo in post liver transplant patient for prevention and management of osteoporosis and bone loss.
Study NCT01674946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oleanolic acid
Description: intraduodenal perfusion
Study NCT01674946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oleic acid
Description: intraduodenal perfusion
Study NCT01674946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: oleic acid
Description: intraduodenal perfusion
Study NCT03063398 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention, this is an observational study
Description: Assessment for exocrine pancreatic insufficiency
Study NCT04993521 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Block type
Description: Regular block type
Study NCT00635167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced-Transrectal Ultrasound
Description: Drug Once a subject is identified TRUS schedule will be set up revolving around the EBRT treatment schedule. A schedule of 6 contrast enhanced TRUS examinations per subject is planned as follows: week 0 (prior to EBRT, baseline \[Visit 2\]); week 5 (middle of treatment \[Visit 3\]); week 10 (end of treatment \[Visit 4\]); week 18 (2 months after end of EBRT \[Visit 5\]); week 26 (4 months after end of EBRT \[Visit 6\]); and week 36 (6 months after end of EBRT \[Visit 7\]).
Study NCT04779060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal fentanyle
Description: 25 mic fentanyle added to heavy bupivacaine for spinal anesthesia
Study NCT04779060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: 8 mg dexamethasone give intrathecally for spinal anaesthesia
Study NCT04779060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: normal saline will be mixed with bupivacaine intrathecally
Study NCT02619552 — intervention group
Intervention type: DRUG
Intervention: Anti-TNF
Description: All participants in this arm receive an anti-TNF for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
Study NCT02619552 — intervention group
Intervention type: DRUG
Intervention: Anti-TNF
Description: All participants in this arm receive an anti-TNF for the treatment of perianal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
Study NCT02619552 — intervention group
Intervention type: DRUG
Intervention: Steroids
Description: All participants in this arm receive steroids for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
Study NCT01915017 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy for Psychosis
Description: The CBT manual to be used for the present study was based upon the work of Kingdon and Turkington (2005) and Granholm et al., (2005) a group-delivered CBT skills training). Available manuals were modified to improve ease of training and to better accommodate the delivery of the full CBT treatment in the home environment. Supervision will be provided throughout the study by D. Turkington and S. Tai world renowned experts in CBT for psychosis. Training will be held for 1-2 weeks annually and supervision will proceed weekly via SKYPE. All therapists will be certified prior to providing treatment for the trial. Sessions are conducted weekly by master's and doctoral level therapists.
Study NCT01915017 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Adaptation Training
Description: CAT supports are established and maintained on weekly home visits by bachelor's and master's level staff. Regular supervision will be provided by the PI who developed CAT.
Study NCT01915017 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-modal Cognitive Therapy
Description: A manual driven intervention combining CBT and CAT. Weekly sessions delivered in the home focus on altering cognitive biases using CBT and bypassing cognitive deficits using environmental supports
Study NCT01915017 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Standard medication follow up and limited case management
Study NCT02592668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Stimulator
Description: Subjects will be implanted with an epidural stimulator onto the dorsal aspect of the lumbosacral spinal cord dura mater. Patients will undergo a structured program of daily physical rehabilitation, treadmill step training, and epidural stimulation to recover motor, sensory, and autonomic function.
Study NCT01883804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyldopa
Description: 6 weeks of Methyldopa administration; where the dose will be increased according to safety of efficacy.
Study NCT01441518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home care
Description: Home care, sometimes called ambulatory care or outpatient, was defined as the blood-glucose self-monitored by the pregnant women at home. This project will provide glucometers to all those who are randomized to home care. The women will receive training for glucose control in pre-defined days, with the glucometer to obtain the mean glucose. According to blood-glucose levels in glycemic profile, insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia .
Study NCT01441518 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital care
Description: Hospital care, sometimes called acute care, was defined as control of maternal diabetes made at hospitals by admission to hospital. The blood-glucose and metabolic control are done in gestational diabetes and mild gestational hyperglycemia treated conventionally.~The hospitalized patients will have their glycemic control done in the hospital. . According to blood-glucose levels in glycemic profile , insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia.~All the women of the study will be accompanied by a team of obstetricians specializing in high-risk pregnancies; residents; dietitians; nurses and neonatologists.
Study NCT03693404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marcaine, Duramorph , ketorolac
Description: Subjects in the SSI group will receive an injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
Study NCT03693404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine (Marcaine)
Description: 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
Study NCT03693404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthetics
Description: Placebo group will only receive standard of care general anesthesia
Study NCT00638755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Carbon Dioxide
Description: Nasal Carbon Dioxide
Study NCT00251589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat 200 mg twice a day for 3 days a week.
Study NCT00251589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat 300 mg once a day for 3 days a week.
Study NCT00251589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat 300 mg twice a day for 3 days a week.
Study NCT00251589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat 400 mg once a day for 21 out of 28 days.
Study NCT00251589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: erlotinib 150 mg once a day.
Study NCT02747407 — intervention group
Intervention type: BIOLOGICAL
Intervention: Hepatitis A Vaccine
Study NCT03139032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD334
Description: APD334 active treatment for 12 weeks.
Study NCT00635141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypertonic saline (7 %) and isotonic saline (0.9%)
Description: Patients in study arm 1 will receive hypertonic saline (7 %) during the first phase of the study and will crossover to placebo (0.9% isotonic saline) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
Study NCT02747407 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02747407 — intervention group
Intervention type: BIOLOGICAL
Intervention: Tetanus Toxoid Vaccine
Study NCT02747407 — intervention group
Intervention type: BIOLOGICAL
Intervention: Trivalent Influenza Vaccine
Study NCT00782301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maraviroc
Description: maraviroc 150 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
Study NCT00782301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etravirine
Description: etravirine 200 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
Study NCT02217514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT04019457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary intervention: Participants receive dietary fibers for a defined number of days.
Study NCT01890317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Description: Induction of mild hypothermia with invasive cooling for 24 hr in addition to primary percutaneous coronary intervention and optimal medical therapy.
Study NCT03358498 — intervention group
Intervention type: OTHER
Intervention: The Medical Outcomes Short-Form 36-Item Health Survey (SF-36v2) It
Description: SF-36v2 is questionnaire comprising 36items measuring eight dimensions of general HRQOL: physical functioning 10 items, physical health problems 4 items, bodily pain 2 items, general health perceptions 5 items, vitality 4 items, social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health 5 items.~.
Study NCT04429412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCT+
Description: Metacognitive training
Study NCT04140539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OTL-101
Description: Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo using a lentiviral vector (LV) encoding the human adenosine deaminase (ADA) gene.
Study NCT03136484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.
Study NCT00635141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypertonic saline (7 %) and isotonic saline (0.9%)
Description: Patients in study arm 2 will receive placebo (0.9% isotonic saline) during the first phase of the study and will crossover to hypertonic saline (7 %) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
Study NCT03136484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canagliflozin
Description: Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.
Study NCT03136484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (canagliflozin)
Description: Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.
Study NCT03136484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.
Study NCT00871260 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: regadenoson
Description: Subjects in open label group will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus) as contrast.
Study NCT02843178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vouchers
Description: A voucher is given that can be used at the cashier of participating grocery stores, corner stores, and farmer's markets, enabling a participant to have the voucher's value subtracted from their grocery bill.
Study NCT02843178 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vouchers
Description: A voucher is given that can be used at the cashier of participating grocery stores, corner stores, and farmer's markets, enabling a participant to have the voucher's value subtracted from their grocery bill.
Study NCT02821091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Dynamic Balance Training
Study NCT03392441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin Deprivation in Type 1 Diabetic Patients
Description: Type 1 Diabetic Patients requiring insulin will have insulin stopped for a short period of time (4-6 hours)
Study NCT03481569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and cerebrospinal fluid pharmacocinetic samples on one of the nine antibiotics prescribed in routine use
Description: Blood and cerebrospinal fluid pharmacocinetic samples at different time point
Study NCT01924741 — intervention group
Intervention type: PROCEDURE
Intervention: ALPPS
Description: Other procedures related to ALPPS like banding of the parechyma with portal vein ligation etc.
Study NCT04494958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination, Palbociclib + Binimetinib
Description: Patients will then start treatment with continuous oral binimetinib 45 mg/BID and palbociclib 100 mg daily, 21 days on / 7 days off, until disease progression. Study treatment will continue until disease progression.~If treatment tolerance is good, after a full cycle patients will be allowed to escalate palbociclib to 125 mg, according to the study investigators' decision. Alternatively, patients with non tolerable grade 2 events will resume at 30 mg/BID of binimetinib upon recovery, maintaining palbociclib at 100 mg 21-on/7-off. Depending on the side-effects, in case of clear relationship with palbociclib is established, palbociclib -instead of binimetinib - will be reduced to 75 mg daily.
Study NCT00758693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine 100 mg/m2 intravenously on days 1 and 2 on a 28-day cycle for 6 cycles
Study NCT00758693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 500 mg/m2 on a 28-day cycle for 6 cycles
Study NCT01279811 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Crossover of vasopressors
Description: To evaluate the effect of different vasopressor agents on SCPP, a crossover intervention will be conducted on patients requiring either NORepinephrine or DOPamine post-operatively, once daily for 5 days while the catheter is in place. A subject on NORepinephrine will be switched over to DOPamine for 1 hr, and then switched back to NORepinephrine. Likewise, a subject on DOPamine will be switched over to NORepinephrine for 1 hr, and then switched back to DOPamine. Subjects on both vasopressors will have DOPamine stopped for 1 hr and NORepinephrine titrated up to maintain the same MAP for 1 hr, and then brought back to the original levels of both vasopressors. On the following day, the reverse will be carried out, with a stoppage of the NORepinephrine and maintenance solely on DOPamine.
Study NCT00628459 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: micronutrient supplementation
Description: Supplements are given daily, 5days/week, for 6 months, involving 15 mg iron (arm 1), 15 mg iron and 10 mg zinc (arm 2), or multiple micronutrient (arm 3): 15 mg iron, 10 mg zinc, 375 µg vitamin A, 5 µg vitamin D, 6 mg vitamin E, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 150 µg folic acid, 0.5 mg vitamin B6, 0.9 mg vitamin B12, 35 mg vitamin C, 10 µg vitamin K, 50 µg iodine, 0.6 mg copper.
Study NCT00628459 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: micronutrient supplementation
Description: Supplements are given daily, 5days/week, for 6 months, involving 15 mg iron (arm 1), 15 mg iron and 10 mg zinc (arm 2), or multiple micronutrient (arm 3): 15 mg iron, 10 mg zinc, 375 µg vitamin A, 5 µg vitamin D, 6 mg vitamin E, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 150 µg folic acid, 0.5 mg vitamin B6, 0.9 mg vitamin B12, 35 mg vitamin C, 10 µg vitamin K, 50 µg iodine, 0.6 mg copper.
Study NCT03678337 — intervention group
Intervention type: OTHER
Intervention: observational cohort with plasma samples
Description: plasma samples
Study NCT02508545 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: perceived egocentric distance (PED) measurements
Study NCT02508545 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight
Study NCT02408172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine was given orally in a dose of 5mg/day to treat patients in the OSA-amlodipine group for 12 weeks.
Study NCT02408172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol
Description: Metoprolol was given orally in a dose of 47.5mg/day to treat patients in the OSA-metoprolol group for 12 weeks.
Study NCT01297803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin_c
Description: 0.02%.1,2,3,minutes match randomized in to two groups(before \&after scleral flap dissection
Study NCT03480893 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: small size interarcuair decompression
Description: A median lumbar incision is made and the paravertebral muscles are dissected subperiosteally and retracted unilaterally or bilaterally. Decompression will be applied via decompression of the ligamentum flavum. The lateral recess will be opened bilaterally and a medial facetectomy will be performed in order maintain stability of the segments. Posterior ligaments will be spared. The wound will be closed in layers with or without a suction drain. Patients will be operated with a loupe magnification or microscope depending on the surgeon's preference.